Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 413-420

  Erkens, C G M ^a   Dinmohamed, A G ^a,b   Kamphorst, M ^c   Toumanian, S ^d   Van Nispen Dobrescu, R ^e   Alink, M ^f   Oudshoorn, N ^g   Mensen, M ^h   Van Den Hof, S ^a,i   Borgdorff, M ^h,i   Verver, S ^a,i  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Rotterdam Rijnmond Public Health Service   (Netherlands)

^d GGD Twente ^*  (Netherlands)

^e GGD Brabant Zuidoost   (Netherlands)

^f GGD Oostelijk Zuid Limburg   (Netherlands)

^g Municipal Medical and Health Service of The Hague   (Netherlands)

^h Amsterdam Health Service   (Netherlands)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cost effectiveness; Interferon gamma release assay; Latent tuberculous infection; Public health resources

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCREENING TEST; TUBERCULIN TEST; COMPARATIVE STUDY; ECONOMICS; EVALUATION STUDY; HEALTH CARE COST; IMMUNOLOGY; LABORATORY DIAGNOSIS; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PREDICTIVE VALUE; REPRODUCIBILITY; UNNECESSARY PROCEDURE; YOUNG ADULT;

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HEALTH CARE COSTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUBERCULIN TEST; UNNECESSARY PROCEDURES; YOUNG ADULT;

EID: 84897127394     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0589     Document Type: Article

References (24)

1. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
2. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
3. Arend S M, Thijsen S F, Leyten E M, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175: 618-627. (Pubitemid 46438947)
4. FrankenWP, Koster B F, Bossink AW, et al. Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results. Clin Vaccine Immunol 2007; 14: 1239-1241. (Pubitemid 47518095)
5. Lalvani A, Richeldi L, Kunst H. Interferon gamma assays for tuberculosis. Lancet Infect Dis 2005; 5: 322-324; author reply 5-7.
6. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 2009; 15: 188-200.
7. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007; 131: 1424-1434. (Pubitemid 46762348)
8. Hardy A B, Varma R, Collyns T, Moffitt S J, Mullarkey C, Watson J P. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERONTB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65: 178-180.
9. Nienhaus A, Schablon A, Costa J T, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011; 11: 247.
10. Pareek M, Watson J P, Ormerod L P, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
11. Thijsen S F, van Rossum S V, Arend S, Koster B, Machiels AM, Bossink AW. The value of interferon gamma release assays for diagnosis infection with Mycobacterium tuberculosis during an annual screening of health care workers. J Occup Environ Med 2008; 50: 1207-1208.
12. Drobniewski F, Cobelens F, Zellweger J P. Use of gamma-interferon assays in low- and medium-prevalence countries in Europe: a consensus statement of a Wolfheze Workshop organised by KNCV/EuroTB, Vilnius, Lithuania, September 2006. Euro Surveill 2007; 12: E070726.2.
13. Kik S V, Franken W P, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35: 1346-1353.
14. Kik S V, Olthof S P, de Vries J T, et al. Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC Public Health 2009; 9: 283.
15. Flores L L, Steingart K R, Dendukuri N, et al. Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis. Clin Vaccine Immunol 2011; 18: 1616-1627.
16. Cartwright WS. Methods for the economic evaluation of health care programmes, second edition. J Ment Health Policy Econ 1999; 2: 43.
17. Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996; 34 (12 Suppl): DS197-199.
18. Mulder C, van Deutekom H, Huisman E M, et al. Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. Eur Respir J 2012; 40: 1443-1449.
19. van Brummelen S E, Bauwens A M, Schlosser N J, Arend S M. Kinetics of a tuberculosis-specific gamma interferon release assay in military personnel with a positive tuberculin skin test. Clin Vaccine Immunol 2010; 17: 937-943.
20. Zwerling A, Benedetti A, Cojocariu M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLOS ONE 2013; 8: e54748.
21. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30: 701-716, viii.
22. Moon H W, Hur M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection: an updated review. Ann Clin Lab Sci 2013; 43: 221-229.
23. Munoz L, Santin M. Interferon-gamma release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: an evidence-based review. J Infect 2013; 66: 381-387.
24. Slump E, Erkens C, van Hunen R, van Rest J F, Schimmel HJ, van Soolingen D. Tuberculose in Nederland 2011. Surveillancerapport. Bilthoven, The Netherlands: National Institute for Public Health and the Environment (RIVM), 2012. [Dutch]